Lupus patients may benefit from engineered immune cells in early trial
NCT ID NCT06310811
First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target lupus. The goal is to check safety and find the right dose in 12 adults with moderate to severe lupus who have not responded well to standard treatments. Participants receive one infusion and are monitored for side effects and disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wuhan Union
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.